{rfName}
An

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Adan AAuthor

Share

December 13, 2021
Publications
>
Article

Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model

Publicated to: Pharmaceutics. 13 (10): 1737- - 2021-10-01 13(10), DOI: 10.3390/pharmaceutics13101737

Authors: García-Otero, X; Mondelo-García, C; González, F; Perez-Fernandez, R; Avila, L; Antúnez-López, JR; González-Barcia, M; Adan, A; Aguiar, P; Otero-Espinar, FJ; Bermúdez, MA; Fernández-Ferreiro, A

Affiliations

Hlth Res Inst Santiago de Compostela IDIS, Paraquasil Grp, Santiago De Compostela 15706, Spain - Author
Hosp Clin Barcelona, Dept Ophthalmol, Barcelona 08036, Spain - Author
Univ Clin Hosp Santiago de Compostela SERGAS, Pathol Anat Dept, Santiago De Compostela 15706, Spain - Author
Univ Clin Hosp Santiago de Compostela SERGAS, Pharm Dept, Santiago De Compostela 15706, Spain - Author
Univ Clin Hosp, Hlth Res Inst Santiago de Compostela IDIS, Clin Pharmacol Grp, Santiago De Compostela 15706, Spain - Author
Univ Clin Hosp, Hlth Res Inst Santiago de Compostela IDIS, Mol Imaging Grp, Santiago De Compostela 15706, Spain - Author
Univ Clin Hosp, Hlth Res Inst Santiago de Compostela IDIS, Ophthalmol Serv, Santiago De Compostela 15782, Spain - Author
Univ Santiago de Compostela Usc, Fac Pharm, Pharmacol Pharm & Pharmaceut Technol Dept, Santiago De Compostela 15705, Spain - Author
Univ Santiago de Compostela Usc, Surg Dept CIMUS, Santiago De Compostela 15706, Spain - Author
Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Dept Physiol, Santiago De Compostela 15706, Spain - Author
See more

Abstract

Uveitis is an infrequent disease which constitutes a major cause of ocular morbidity. Correct management is essential, being corticosteroids its cornerstone. In case of contraindication to corticosteroids or treatment failure, the use of topical tacrolimus (TAC) could be an alternative which has already demonstrated safety and effectiveness in other ocular pathologies. However, TAC eye drops are not marketed, thus their elaboration must be carried out in Hospital Pharmacy Departments (HPDs).32 Sprague-Dawley rats were divided into 4 groups of 8 rats each: (a) untreated healthy rats (Healthy); (b) untreated Endotoxin-Induced Uveitis model-rats (EIU); (c) EIU-rats treated with standard treatment of dexamethasone ophthalmic drops (DXM) and (d) EIU-rats treated with TAC-hydroxypropyl-?-cyclodextrin eye drops previously developed by our group (TAC-HP?CD). The mRNA expression levels of IL-6, IL-8, MIP-1? and TNF-?, quantitative analysis of leucocytes in aqueous humor and histological evaluation were performed.TAC-HP?CD eye drops demonstrated to reduce ocular inflammation, expression of IL-6, TNF-?, MIP-1? and leukocyte infiltration in aqueous humor.TAC-HP?CD eye drops showed beneficial effect in EIU model in rats, positioning as an alternative for uveitis treatment in case of corticosteroids resistance or intolerance.

Keywords

autoimmuneefficacyeye dropshydroxypropyl-beta-cyclodextrinimmunosuppressantsinterleukinsintravitreal injectionmechanismspharmacokineticsposteriorsusceptibility locitacrolimustacrolimus fk506therapyEndotoxin-induced uveitisEye dropsHydroxypropyl-?-cyclodextrinHydroxypropyl-β-cyclodextrinImmunosuppressantsInterleukinsTacrolimusWide association analysis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Pharmaceutics due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 39/279, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-16:

  • WoS: 6
  • Europe PMC: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 27.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 27 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Awards linked to the item

This project was partially funded by Health Research Institute Carlos III (PI20/00719, RETICS RD16/0008/0003), FEDER, Axencia Galega Innovacion (Grupos de Potencial Crecimiento IN607B2020/11 y Grupo de Referencia Competitiva ED431C2021/01) and Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100). X. Garcia-Otero is grateful to the IDIS (Health Research Institute of Santiago de Compostela) for financing his predoctoral research fellowship. C. Mondelo-Garcia and A. Fernandez-Ferreiro are grateful to the Carlos III Health Institute for financing their personnel contracts: JR20/00026 and JR18/00014.